New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease Jul 20, 2022 | 2018, Frontiers in Pharmacology, Publication - legacy work ‹ Previous Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury Next › Legacy data sharing to improve drug safety assessment: the eTOX project
